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ABSTRACT 
Context: Shilajit is a natural rock exudate used to prevent and combat problems with diabetes. It also has 
antioxidant, hypolipidemic and hypoglycaemic properties. Aim: To evaluate the effect of Shilajit on 
endothelial function in type 2 diabetes mellitus patients. Settings and Design: Randomized, double blind, 
placebo-controlled study. Methods and Material: After the ethics committee approval and informed consent, 
forty subjects were randomized to receive either Shilajit 250 mg or placebo (two capsules twice daily for 12 
weeks). Endothelial function was evaluated with Reflection index (RI), Augmentation index (AIx), 
Subendocardial viability ratio (SEVR), Ankle Brachial Index (ABI), Pulse wave velocity(PWV) and Systemic 
vascular resistance (SVR) at baseline,4,8,12 weeks. Lipid profile and biomarkers Nitric oxide, MDA, 
Glutathione, hsCRP were evaluated at baseline and post treatment. Statistical analysis used: Data was 
expressed as mean ±SD. Paired and unpaired t- tests were performed for within group and between groups 
analysis, respectively. A p value < 0.05 was considered statistically significant. Results: After 12 weeks of 
treatment, Shilajit produced statistically significant increase in mean RI from baseline (-2.29±1.43 to -
8.61±2.70; p<0.001) and in mean SEVR (145.5±24.89 to 150.9±24.08; p<0.05). Compared to placebo, Shilajit 
produced statistically significant increase in mean percentage change with RI, AIx, SEVR, and SVR, suggesting 
improvement in endothelial function. There was also statistically significant reduction in hsCRP, MDA, total 
cholesterol, LDL-C, triglycerides and increase in NO, GSH, HDL-C. The drug was well tolerated and no subjects 
discontinued due to adverse drug reactions. Conclusion: Shilajit showed significant improvement in 
endothelial function as evidenced with change in reflection index. It also improved other cardiovascular 
parameters and biomarker levels. Further studies are warranted in more number of subjects. 
KEYWORDS: Augmentation index, reflection index, cardiovascular disease, Shilajit.  
INTRODUCTION 
 Cardiovascular disease (CVD) is the number one 
cause of death globally.[1] Smoking, hypertension, high LDL 
cholesterol, low HDL cholesterol and diabetes mellitus are 
the five major risk factors for CVD.[2] Diabetes is associated 
with an increased risk of atherosclerosis, which may result 
in coronary artery disease.[3] Physiological changes seen in 
Diabetes mellitus (DM) patients,, include platelet hyper-
reactivity, a tendency for negative arterial remodelling, 
impaired fibrinolysis, increased inflammation, and 
endothelial dysfunction.  
 Endothelial dysfunction is the cause of 
atherogenesis and associated with late-stage adverse 
outcomes.[4] This endothelial dysfunction results from 
reduced bioavailability of the vasodilator nitric oxide (NO) 
mainly due to accelerated NO degradation by reactive 
oxygen species.[5] The superoxide production due to 
oxidative stress is the common pathogenic factor in 
development of diabetes mellitus and complications 
associated with DM. Most of the therapies aimed at 
reducing stress would benefit patients with type 2 DM and 
those at risk for developing diabetes.[6,7,8] 
 Many herbs possess potent antioxidant, anti-
inflammatory and cardio-protective properties and are 
used by patients with increased risk of cardiovascular 
morbidity and mortality. Shilajit, a natural rock exudate 
containing various bioactives, finds extensive use in 
Ayurveda for diverse clinical conditions. The active 
constituents of Shilajit include dibenzo-alpha-pyrones and 
related metabolites, small peptides (constituting non-
protein amino acids), some lipids and carrier molecules 
(fulvic acids).[9,10,11] For centuries people living in the 
isolated villages in Himalayas and adjoining regions have 
used Shilajit alone or in combination with other plant 
remedies to prevent and combat problems with 
diabetes.[12] Also, being an antioxidant Shilajit prevents 
damage to the pancreatic islet cell induced by the cytotoxic 
oxygen radicals.[13,14] 
 It has been proposed that the derangement of 
glucose, fat and protein metabolism during diabetes 
results into the development of hyperlipidemia.[15] In a 
study, Shilajit produced significant beneficial effects in 
lipid profile in diabetic rats by reducing total cholesterol, 
triglycerides and increasing HDL significantly.[16] But very 
less information is available about the effects of Shilajit in 
human diabetic patients. Therefore the present study was 
planned to evaluate the effect of Shilajit on endothelial 
function in type 2 diabetes mellitus patients and to further 
study the probable mechanism of action.  
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Objectives 
1). To evaluate the effect of Shilajit on endothelial function 
in type 2 diabetes mellitus patients and to further study 
the probable mechanism of action.  
2). To study the biomarkers responsible for endothelial 
dysfunction with change in levels of free radical and 
inflammatory biomarkers (hsCRP). 
3). To evaluate the safety and tolerability of study 
medications. 
Materials and Methods 
 This was a prospective, randomized, double blind 
multi-dose, cross-over, placebo controlled study conducted 
after approval of the Institutional Ethics Committee of 
Nizam's Institute of Medical Sciences (NIMS), Hyderabad, 
India. All subjects gave written informed consent prior to 
participation in the study. 
Study participants 
 A total of 50 patients were screened for eligibility 
to participate in this study. Forty patients of either sex, 
aged 18-75 years were screened for their eligibility to 
participate in the study with complete medical history, 
physical examination, hematological and biochemical 
screening, electrocardiogram and chest X-ray. Patients of 
either sex, aged 18-75 years, with fasting plasma glucose of 
≥110 mg/dL, a glycosylated haemoglobin (HbA1c) 
between 7 % and 9% and taking stable dose of anti-
diabetic treatment (Metformin 1500-2500mg/day) for the 
past 8 weeks prior to the screening visit and having 
endothelial dysfunction defined as ≤ 6% change in 
reflection index (RI) on post salbutamol challenge test 
were included in the study. Patients with severe 
uncontrolled hyperglyceamia, uncontrolled hypertension, 
cardiac arrhythmia, impaired hepatic or renal function, 
history of malignancy or stroke, smoking, chronic 
alcoholism, any other serious disease requiring active 
treatment and treatment with any other herbal 
supplements, were excluded from the study. The subjects 
were excluded from study if there was any evidence of 
physical illness, drug abuse or abnormal laboratory 
parameters.  
 Eligible subjects were trained on the test 
procedure on two prior occasions to make them familiar 
with the testing device and test procedure. All the 
recordings were carried out in the morning between 7.30 
am and 10:00 am after a light breakfast. 
Study medication 
 The study medications included capsules of 
Shilajit (250 mg strength) and placebo. Each Shilajit 
250mg capsule consisted of purified aqueous extract of 
rock exudates containing dibenzo-ɑ-pyrones, dibenzo-ɑ-
pyrone chromoproteins and fulvic acids as bioactives. 
Purified Shilajit was manufactured by a totally aqueous 
extraction process using raw material obtained from the 
Himalayas at about 10,000 feet altitude. After multiple 
extractions and removal of heavy metals, the liquid extract 
was dried by rotary vacuum drying and milled to specified 
particle size. 
 Each placebo capsule contained microcrystalline 
cellulose (49.7% w/w), lactose (49.5%) and magnesium 
stearate (0.69% w/w). Both study medications were 
supplied by Natreon, Inc. USA. 
Study Procedure  
 After screening, all the eligible subjects were 
randomized to receive either one of the two treatments for 
a duration of 12 weeks. Subjects in Group1 received one 
capsule of Shilajit 250mg twice daily and subjects in Group 
2 received one capsule of placebo twice daily. Subjects 
were asked to review for follow up visits at 4, 8 and 12 
weeks of therapy. At each visit they were evaluated for 
efficacy and safety. Pharmacodynamic evaluation for 
endothelial function was conducted at every visit. Blood 
sample was collected for evaluation of biomarkers before 
and at end of treatment. Safety lab investigations for 
haematological, hepatic and renal biochemical parameters 
were conducted before and at the end of the study and also 
as and when required. Subjects were enquired for the 
presence of any ADRs and the same was recorded in the 
case report form. Compliance to therapy was assessed by 
pill count method. 
Procedure for Assessment Of Endothelial Function 
 A salbutamol challenge test employing digital 
volume plethysmography was used to assess endothelial 
function as reported by Chowienczyk et al.[17] and Naidu et 
al.[18] The patients were examined in supine position after 
5 minutes of rest. A digital volume pulse (DVP) was 
obtained using photo plethysmograph (Pulse Trace PCA2, 
PT200, Micro Medical, Gallingham, Kent, UK) transmitting 
infra red light at 940 nm, placed on the index finger of 
right hand. The signal from the plethysmograph was 
digitized using a 12 bit analogue to digital converter with a 
sampling frequency of 100 Hz. DVP waveforms were 
recorded over 20 second period and the height of the late 
systolic / early diastolic portion of the DVP was expressed 
as a percentage of the amplitude of the DVP to yield the 
reflection index (RI), as per the procedure described in 
detail by Millasseau et al.[19] After DVP recordings had 
been taken, three measurements of reflection index (RI) 
were calculated and the mean value was determined. 
Subjects were then administered 400µg of salbutamol by 
inhalation. After 15 minutes three measurements of RI 
were obtained again and the difference in mean RI before 
and after administration of salbutamol was used for 
assessing endothelial function. A change of ≤ 6% in RI post 
salbutamol was considered as endothelial dysfunction. 
Measurement of wave reflection indices 
 Arterial stiffness was measured by using a 
validated, commercially available system (SphygmoCor; 
AtCor Medical, Australia) that employs the principle of 
applanation tonometry and appropriate acquisition and 
analysis software for non-invasive recording and analysis 
of the arterial pulse. Augmentation index (AIx) and 
augmented pressure of the central (aortic) pressure 
waveforms were measured as indices of wave reflections. 
The AIx is a composite measure of the magnitude of wave 
reflections and arterial stiffness, which affects timing of 
wave reflections. Because the augmentation index is 
influenced by changes in heart rate (HR), it was also 
accordingly corrected. The central (aortic) arterial 
pressure was derived from radial artery recordings, with 
the use of a generalized transfer function that has been 
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shown to give an accurate estimate of the central arterial 
pressure waveform and its characteristics. Waveforms of 
radial pressure were calibrated according to sphygmo-
manometric systolic and diastolic pressure measured in 
the brachial artery because there is practically negligible 
pressure pulse amplification between the brachial and the 
radial artery. The subendocardial viability index, an 
indicator of myocardial workload and perfusion (O2 supply 
vs. demand) was calculated as the ratio of the integral of 
diastolic pressure and time to the integral of systolic 
pressure and time.  
 Brachial-ankle pulse wave velocity (baPWV) was 
also used to evaluate arterial stiffness. Pulse wave velocity 
is the speed at which the blood pressure pulse travels from 
the heart to the peripheral artery after blood rushes out 
during contraction. It is mainly used to evaluate stiffness of 
the artery wall. Pulse wave velocity increases with 
stiffness of the arteries. The PTT (Pulse Transit Time) of 
each segment is calculated from the waveform taken from 
each sensor. It calculates heart-brachial PWV of both 
upper limbs, heart-ankle PWV of both lower limbs, 
brachial-ankle PWV of both right and left limb pairs and 
effective estimated carotid-femoral PWV is calculated. 
 Brachial Ankle Pulse Wave Velocity (baPWV), 
Ankle Brachial Index (ABI) and Blood Pressure (BP) were 
measured using an automatic waveform analyzer (BP-203 
RPE; Colin, Japan). Measurements were taken with 
patients lying in a supine position after 5 minutes of rest in 
that position. Pressure waveforms of the brachial and 
tibial arteries were then recorded simultaneously by an 
oscillometric method. Measurement of right and left 
baPWV was obtained for an average of 10 seconds. The 
average of left and right baPWV was used for analysis. 
Method for recording of Cardiac output (Lt/min) 
 Recording of cardiac output was performed using 
L&T Nivomon monitor, that works on the features of 
impedence plethysmography principle.  
Biomarker evaluation 
 Nitric oxide, Malondialdehyde (MDA) and 
Glutathione levels were estimated spectrophotometrically 
and hsCRP (high sensitivity C-reactive protein) by ELISA 
method. 
 After the baseline test measurements, the subjects 
were discharged with study medications for 12weeks and 
were instructed to take 2 capsules twice daily with 240 ml 
of water. The same test procedure was again repeated 
after 12 weeks of treatment to obtain post treatment 
values. Samples were collected after an overnight fast of 
12hrs after the last dose of medication for determination 
of haemoglobin, HbA1c, blood urea and serum creatinine, 
liver function test and lipid profile. A washout period of 10 
days was given between the treatments. Subjects were 
then crossed over to receive the second formulation of 2 
capsules twice daily for 12weeks for Run II. All the test 
procedures described for Run I were repeated pre and 
post treatment. 
Efficacy Parameters 
 The primary efficacy measure was a change in 
endothelial dysfunction as assessed by more than 6% 
change in reflection index at 12 weeks in all the treatment 
groups. Secondary efficacy measures included change in 
oxidative stress markers, serum levels of nitric oxide at 12 
weeks in all the treatment groups and also evaluation of 
safety and tolerability of the test medications. 
Safety Assessments 
 All the subjects had undergone complete physical 
examination, safety lab evaluations at baseline and at the 
end of the treatment.  
Statistical Analysis 
 Data was expressed as mean ± SD. Paired and 
unpaired t- tests were performed for within group and 
between groups analysis, respectively. A p-value < 0.05 
was considered to be statistically significant. All statistical 
analysis was performed using the Graphpad Prism 5, 
Sandiego, CA, USA. 
Results  
 A total of 50 subjects were screened and 40 
eligible subjects, 20 each in Shilajit 250mg and placebo 
groups completed the study. The demographic 
characteristics of both the groups are shown in Table 1. 
There was no significant difference between treatment 
groups in the baseline characteristics.  
Table 1: Demographic characteristics of the two study Groups 
Parameter Shilajit (A) Placebo (B) 
Total No. n=20 n=20 
Gender(M/F) 16/4 14/6 
Age (yrs) 54.85±9.32 55.75±7.62 
Weight (Kg) 64.01±9.23 64.35±6.46 
BMI(Kg/m2 ) 24.68±2.93 24.70±2.42 
Table 2: Effect of Shilajit and Placebo on pharmacodynamic parameters after 12 weeks of treatment 
 RI (%) AIx (%) SEVR(%) ABI PWV(cm/s) CO (Lt/min) SVR 
(dyne.sec/cm5) 
 Shilajit (A) (n=20) 
Pre-treatment -2.29±1.43 144.54±12.93 145.3±24.89 1.05±0.07 1569±194.09 4.76±1.02 1564±437.67 
 Post-treatment -8.61±2.70  
$ 
139.30±10.30 
# 
150.9±24.08 
# 
1.06±0.07 NS 1525±136.2 
NS 
4.98±0.98 
NS 
1450±316.25 
NS 
 Absolute 
Change 
-6.32±2.54  
$ 
 
-5.24±8.40 
# 
5.55±10.76 
# 
0.017±0.09 
NS 
-43.75±148.9 
NS 
0.2±0.41 NS -113.6±405.01 
NS 
 Mean Percent -273.9±92.85 -3.36±5.47 4.28±8.51 0.95±9.20 NS -1.06±9.47 1.09±9.36 -4.61±18.03 
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Change $ $ $ NS NS NS 
 Placebo (B) (n=20) 
Pre-treatment -2.41±1.08 146.05±13.12 147.3±21.59 1.05±0.06 1583±147.93 4.47±0.62 1425±203.25 
 Post-treatment -1.33±2.72 
NS 
147.55±12.93 
NS 
146.9±20.59 
NS 
1.054±0.06 
NS 
1592±149.73 
NS 
4.38±0.62 
NS 
1483±234.10 
NS 
 Absolute 
Change 
1.08±2.34 
 
1.50±3.50 
 
0.34±2.82 
 
0.004±0.03 
 
8.75±56.71 
 
-0.09±0.20 
 
58.95±179.52 
 Mean Percent 
Change 
24.49±53.67 1.07±2.42 -0.11±1.99 0.47±3.35 0.6±3.48 -1.91±4.72 4.77±13.85 
# p<0.01, $ p<0.001,NS-Non-significant, compared to baseline. In Absolute change: # p<0.01 AVs B; $–p<0.001 AVs B; NS 
– Not significant A Vs B. In Mean percentage change: $–p<0.001 AVs B; Not significant A Vs B 
 Compared to baseline, treatment with Shilajit for 12 weeks resulted in significant increase in reflection index 
(p<0.001) and SEVR (p< 0.01) and significant decrease in Augmentation index (p< 0.01) (Table 2). When compared to 
placebo, treatment with Shilajit for 12 weeks in demonstrated significant difference in reflection index (p<0.001), SEVR 
(p< 0.001) and Augmentation index (p< 0.001) (Table 2). 
Table 3: Effect of Shilajit and Placebo on biomarkers after 12 weeks of treatment 
 NO (µM/L) MDA(nmol/ml) GSH (µM/L) hsCRP(mg/L) 
Shilajit (A) (n=20) 
Pre-treatment 27.39 ±10.21 3.40±0.65 418.22±128.03 2.59±0.98 
Post-treatment 35.51± 12.08  
# 
2.73±0.55 
 # 
524.78±145.41 
$ 
1.07±0.33  
# 
Absolute Change 8.12±6.30  
$ 
-0.67±0.45 
$ 
106.56±125.43 
$ 
-1.51±0.85 
$ 
Mean Percent 
Change 
31.07±24.45 
$ 
-19.05±13.07 
$ 
30.00±32.76 
$ 
-52.1±27.04 
$ 
 Placebo (B) (n=20) 
Pre-treatment 30.17± 8.35 3.37±0.67 423.91±93.0 2.51±1.03 
Post-treatment 29.41 ±7.49 
NS 
3.42±0.60 
NS 
423.2±91.51 
NS 
2.44±0.99 
NS 
Absolute Change -0.76±2.50 0.05±0.55 -0.71±11.95 -0.07±0.29 
Mean Percent 
Change 
-1.62±8.74 
 
3.11±14.68 
 
-0.01±3.37 
 
-1.33±10.40 
 
# p<0.01 compared to baseline, $ p<0.001 compared to baseline. In Absolute change: $–p<0.001 AVs B; In Mean 
percentage change: $–p<0.001 AVs B 
 At the end of 12 weeks, compared to baseline, Shilajit treatment resulted in significant increase in nitric oxide (p< 
0.01) and GSH (glutathione) (p<0.001) levels and significant decrease in malondialdehyde (p< 0.01) and hsCRP (p< 0.01) 
levels (Table 3). The absolute and mean percentage changes in Shilajit group were significantly different from placebo 
group at the end of 12 weeks of treatment (Table 3). 
Table No.4: Effect of Shilajit and Placebo after 12 weeks of treatment on lipid profile and Glycosylated hemoglobin 
(HbA1c) 
 Total 
cholesterol(mg/dl) 
HDL (mg/dl) LDL 
(mg/dl) 
Triglycerides 
(mg/dl) 
VLDL  
(mg/dl) 
HbA1c (%) 
Shilajit (A) (n=20) 
Pre-treatment 176.85±21.50 39.45±4.35 110.7±17.06 131.93±36.37 27.45±12.53 7.78±0.50 
Post-treatment 152.90±36.04 
# 
42.35±6.24 
* 
98.65±21.30 
$ 
113.8±37.93 
$ 
22.9±9.05 
* 
7.05±0.5 
$ 
Absolute Change -23.95±23.30 
$ 
2.90±6.03 
# 
-12.10±17.46 
# 
-18.13±27.09 
# 
-4.55±7.53 
$ 
-0.74±0.56 
$ 
Mean Percent 
Change 
-14.13±13.57 
$ 
7.90±16.40 
* 
-10.06±16.73 
# 
-12.61±17.21 
# 
-13.8±16.72 
$ 
-9.25±6.73 
$ 
 Placebo (B) (n=20) 
Pre-treatment 170.70±26.34 39.15±5.63 111.95±20.49 140.2±16.16 28.75±5.83 7.62±0.39 
Post-treatment 177.10±17.04 
NS 
38.00±4.77 
NS 
113.95±19.97 
NS 
142.45±18.63 
NS 
29.00±5.94 
NS 
7.54±0.45 
NS 
Absolute Change 7.05±18.63 -1.15±2.80 2.0±5.35 2.25±6.16 0.25±1.89 -0.08±0.27 
Mean Percent 
Change 
5.08±11.87 -2.39±7.29 2.05± 4.89 1.50±4.25 0.98±6.61 -1.03±3.50 
Absolute change: # p<0.01 AVs B; $–p<0.001 AVs B; In Mean percentage change: * - p<0.05 AVs B; # p<0.01 AVs B; $–
p<0.001 AVs B 
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 Treatment with Shilajit significantly reduced total 
cholesterol (p<0.01), LDL-cholesterol (p<0.0), triglycerides 
(p<0.001), VLDL-cholesterol (p<0.05) and HbA1c 
(p<0.001) levels and increased HDL-cholesterol (p<0.05)at 
the end of 12 weeks, compared to baseline (Table 4). When 
compared to placebo, treatment with Shilajit for 12 weeks 
produced a favourable lipid profile and improved HbA1c 
levels, as observed by the significant differences in 
absolute change and mean percentage change of metabolic 
parameters in the two treatment groups.  
Safety 
 At post treatment, there were no significant 
changes in vital, hematological, renal and hepatic 
functions. Three patients in Shilajit treatment group 
complained of headache mild in intensity and two with 
dyspepsia in placebo group. Both the treatments were well 
tolerated. There was no serious adverse event recorded in 
the study. 
DISCUSSION 
 Type 2 diabetes is a global epidemic and studies 
have revealed an associated two- to fourfold increased risk 
of cardiovascular disease. This has been attributed to the 
adverse effects of hyperglycemia and oxidative stress on 
vascular biology. Also, patients with impaired fasting 
glucose and impaired glucose tolerance are at increased 
risk of cardiovascular disease. [20] One of the important risk 
factors for the development of cardiovascular pathology is 
endothelial dysfunction. The physiology of endothelium 
has been actively researched in the last few years and 
evidence suggests that endothelium has an important role 
in regulating vascular tone and structure. A healthy 
endothelium has been shown to inhibit platelet and 
leukocyte adhesion to the vascular surface thus 
maintaining a balance of profibrinolytic and 
prothrombotic activity.[21] Endothelial dysfunction, which 
refers to an impairment of the ability of the endothelium to 
properly maintain vascular homeostasis, [22] significantly 
contributes to the pathogenesis and clinical manifestation 
of atherosclerosis and has been linked to Type 2 diabetes 
mellitus and insulin resistance in experimental and clinical 
studies. [23]  
 The characteristic feature of endothelial 
dysfunction is reduction of the bioavailability of 
vasodilators, especially nitric oxide (NO), and an increase 
in endothelium-derived contracting factors. [24] This leads 
to an impairment of endothelium-dependent vasodilation 
and development of a specific state of endothelial 
activation, resulting in pro-inflammatory, proliferative, 
and pro-coagulatory states that favour all stages of 
atherogenesis. [25] Thus, endothelial function may serve as 
a marker of an unfavourable cardiovascular prognosis. [26] 
 Treatment of endothelial dysfunction includes use 
of cholesterol lowering drugs, antioxidants, angiotensin 
converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers, fibrates, thiazolidinediones, estrogen 
replacement therapy, L-Arginine supplementation, 
tetrahydrobiopterin, or stimulators of endothelial 
progenitor cells. [27, 28]  
 Studies conducted by the practitioners of 
Ayurvedic, Chinese and Unani medicine to manage the 
cardiovascular complications in diabetic patients have 
indicated that it is rational to use our natural resources 
along with current therapy to identify inexpensive and 
safer strategies for managing cardiovascular disease. [29] 
Shilajit is a natural rock exudate that possesses antioxidant 
activity. [30] In this study, we evaluated the effect of Shilajit 
250 mg and placebo on endothelial function in patients 
with type 2 diabetes.  
 Shilajit treatment for 12 weeks improved the 
arterial stiffness in patients which was evident by a 
significant increase in the reflection index (RI) and 
subendocardial viability ratio (SEVR) and a reduction in 
augmentation index (AIx), compared to baseline and 
placebo. Subendocardial viability ratio (SEVR) is an index 
of myocardial oxygen supply and demand. [31] AIx has been 
shown to be predictive for coronary artery disease. [32] The 
improvement in the parameters of arterial stiffness can be 
attributed to the cardioprotective property of Shilajit 
mediated by it’s anti-oxidant effects.[33] Experimental 
studies have further demonstrated the elevation of 
endogenous antioxidants on treatment with Shilajit. [33] 
Also, Shilajit treatment was shown to have beneficial effect 
against experimentally induced myocardial necrosis, [33] 
which possibly explains it’s probable beneficial role in 
coronary artery disease. Interestingly, results from 
recently concluded experimental studies evaluating the 
cardioprotective activity of Shilajit indicate that other 
mechanisms than reinforcements of antioxidant system 
are involved in the cardioprotective beneficial effect of 
Shilajit. [34] 
 The effect of Shilajit treatment on oxidative stress 
biomarker levels was evaluated to elucidate the anti-
oxidant activity of Shilajit formulation. There was a 
significant increase from baseline in the levels of nitric 
oxide (vasodilatory and anti-oxidant) and glutathione 
(anti-oxidant) and significant reductions in the levels of 
malondialdehyde (MDA, oxidative stress marker) and high 
sensitivity C-reactive protein (inflammatory marker) in 
patients who were treated with Shilajit for 12 weeks, thus 
demonstrating the anti-oxidant and anti-inflammatory 
properties of Shilajit. The anti-oxidant property of Shilajit 
has been extensively studied under experimental 
conditions with convincing results.[35] Evidence shows that 
Shilajit is a source of natural antioxidants.[35] Further, it 
has been shown that Shilajit has potent scavenging activity 
against lipid peroxidation products.[35] In our study, Shilajit 
significantly reduced MDA levels, which is a marker of lipid 
peroxidation.[35] By increasing the levels of nitric oxide, 
Shilajit has demonstrated inherent vasodilator property 
that is further possibly responsible for the restoration of 
imbalance between vasodilator and vasoconstrictor effects 
of damaged endothelium in diabetes patients. It has also 
been shown that Shilajit increases glutathione levels when 
it has been decreased by experimentally induced oxidative 
stress.[36] In our study there was a significant increase in 
glutathione levels in Shilajit group at the end of 12 weeks. 
The anti-inflammatory activity of Shilajit has been 
demonstrated under experimental conditions.[37] High 
sensitivity C reactive protein (HSCRP) is an inflammatory 
biomarker that is a potent independent predictor of 
myocardial infarction and stroke in healthy men and 
women. [38] Treatment with Shilajit in our study has 
significantly reduced the levels of HSCRP, thus 
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demonstration anti-inflammatory and cardioprotective 
properties.  
 Metabolic indicators including lipid parameters 
and glycosylated haemoglobin were also evaluated in 
patients of both study groups. In our study, treatment with 
Shilajit significantly improved the lipid profile and 
glycemic control at the end of 12 weeks. Studies in 
experimental models suggest that the beneficial effects of 
Shilajit on lipid profile in subjects with diabetes is due to 
better glycemic control induced by it.[39] However, direct 
beneficial effects of Shilajit on lipid profile also exist. [39] 
The most probable mechanism of hypoglycaemic effects of 
Shilajit is it’s ability to protect pancreatic beta cell function 
secondary to it’s anti-oxidant effect. [40] Gupta et al 
suggested that long-term treatment with Shilajit increases 
the number of β-cells of pancreas (pancreatotrophic 
action), which may result in better sensitivity of pancreatic 
β- cells with prompt secretion of a large quantity of insulin 
in response to hyperglycemia. [40] Shilajit was well 
tolerated by patients in our study with no serious adverse 
events. 
CONCLUSION 
 The purified aqueous extract of Shilajit showed 
significant improvement in endothelial function as 
evidenced with change in reflection index, SEVR and 
augmentation index. It also improved other cardiovascular 
& metabolic parameters and biomarker levels, 
demonstrating cardioprotective, anti-oxidant, anti-
inflammatory, hypoglycaemic and lipid friendly effects. 
However, further studies are warranted to evaluate these 
beneficial effects of Shilajit in more number of subjects.  
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